Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Biotechnology - Page 63

Biotechnology

Health Canada authorized Moderna COVID-19 vaccine in Canada
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Health Canada authorized Moderna COVID-19 vaccine in Canada

On Dec. 23, 2020, Moderna announced that Health Canada had authorized its vaccine against COVID-19 for the immunization…

Read More Health Canada authorized Moderna COVID-19 vaccine in CanadaContinue

Mink at affected Oregon farm negative for SARS-CoV-2, wildlife surveillance continued
Agriculture | Biotechnology | COVID-19 | Infectious Disease | USDA | Veterinary

Mink at affected Oregon farm negative for SARS-CoV-2, wildlife surveillance continued

On Dec. 23, 2020, recent tests confirmed mink that tested positive for SARS-CoV-2 at an Oregon farm in…

Read More Mink at affected Oregon farm negative for SARS-CoV-2, wildlife surveillance continuedContinue

Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen
Biotechnology | COVID-19 | FDA | Therapeutics

Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigen

On Dec. 22, 2020, Sorrento Therapeutics announced that an Emergency Use Authorization (EUA) Application had been submitted to…

Read More Sorrento announced it had submitted an EUA application to the FDA for COVI-STIX rapid test for detection of SARS-CoV-2 antigenContinue

RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation

On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…

Read More RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendationContinue

Cocrystal Pharma selected lead compound for further development against Coronaviruses
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

Cocrystal Pharma selected lead compound for further development against Coronaviruses

On Dec. 22, 2020, Cocrystal Pharma announced the selection of CDI-45205 as the lead compound for further development…

Read More Cocrystal Pharma selected lead compound for further development against CoronavirusesContinue

Reston Ebolavirus spreads efficiently in pigs
Biotechnology | Environmental | Infectious Disease | NIH

Reston Ebolavirus spreads efficiently in pigs

On Dec. 21, 2020, the U.S. National Institutes of Health (NIH) announced a study published in the Proceedings…

Read More Reston Ebolavirus spreads efficiently in pigsContinue

New SARS-CoV-2 variant identified through viral genomic sequencing in United Kingdom and Northern Ireland
Biotechnology | COVID-19 | Diagnostics | Genomics | Vaccine | WHO

New SARS-CoV-2 variant identified through viral genomic sequencing in United Kingdom and Northern Ireland

On Dec. 21, 2020, the WHO reported that authorities of the United Kingdom of Great Britain and Northern…

Read More New SARS-CoV-2 variant identified through viral genomic sequencing in United Kingdom and Northern IrelandContinue

U.S. Dept. of Veterans Affairs began COVID-19 vaccinations at 128 additional sites
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. Dept. of Veterans Affairs began COVID-19 vaccinations at 128 additional sites

On Dec. 21, 2020, the U.S. Dept. of Veterans Affairs (VA) announced that it had begun COVID-19 vaccinations…

Read More U.S. Dept. of Veterans Affairs began COVID-19 vaccinations at 128 additional sitesContinue

European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU
Agriculture | Biotechnology | Diagnostics | Disease | Therapeutics

European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EU

On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of…

Read More European Commission approved Aimmune’s PALFORZIA as first-ever treatment for peanut allergy in the EUContinue

Quidel received Emergency Use Authorization for QuickVue SARS rapid antigen test for COVID-19 diagnosis
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza

Quidel received Emergency Use Authorization for QuickVue SARS rapid antigen test for COVID-19 diagnosis

On Dec. 21, 2020, Quidel announced that it had received Emergency Use Authorization from the U.S. Food and…

Read More Quidel received Emergency Use Authorization for QuickVue SARS rapid antigen test for COVID-19 diagnosisContinue

CDC’s ACIP announced interim recommendation for use of Moderna COVID-19 Vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

CDC’s ACIP announced interim recommendation for use of Moderna COVID-19 Vaccine

On Dec. 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices…

Read More CDC’s ACIP announced interim recommendation for use of Moderna COVID-19 VaccineContinue

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine

Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY

On Dec. 19, 2020, Pfizer and BioNTech announced they supplying an additional 100 million doses of COMIRNATY the…

Read More Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATYContinue

FDA approved first adjuvant therapy for most common type of lung cancer
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics

FDA approved first adjuvant therapy for most common type of lung cancer

On Dec. 18, 2020, the the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Tagrisso (osimertinib) as the…

Read More FDA approved first adjuvant therapy for most common type of lung cancerContinue

National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

National Research Council of Canada supported development of 4 COVID-19 therapeutic candidates

On Dec. 18, 2020, the National Research Council of Canada (NRC) announced it was providing advisory services and…

Read More National Research Council of Canada supported development of 4 COVID-19 therapeutic candidatesContinue

FDA issued Emergency Use Authorization for second COVID-19 vaccine
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

FDA issued Emergency Use Authorization for second COVID-19 vaccine

On Dec. 18, 2020, the FDA issued an emergency use authorization (EUA) for the second vaccine for the…

Read More FDA issued Emergency Use Authorization for second COVID-19 vaccineContinue

Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

On Dec. 18, 2020, Eli Lilly announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in…

Read More Lilly began pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New MexicoContinue

EC exercised option for additional 80 million doses of Moderna’s COVID-19 vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

EC exercised option for additional 80 million doses of Moderna’s COVID-19 vaccine candidate

On Dec. 18, 2020, Moderna announced that the European Commission (EC) had exercised its option to purchase an…

Read More EC exercised option for additional 80 million doses of Moderna’s COVID-19 vaccine candidateContinue

Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.

On Dec. 18, 2020, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…

Read More Moderna announced FDA authorization of Moderna COVID-19 vaccine in U.S.Continue

CDC Advisory Committee on Immunization Practices recommended vaccination with Moderna’s COVID-19 vaccine
Biotechnology | CDC | COVID-19 | Infectious Disease | Vaccine

CDC Advisory Committee on Immunization Practices recommended vaccination with Moderna’s COVID-19 vaccine

On Dec. 18, 2020, Moderna announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on…

Read More CDC Advisory Committee on Immunization Practices recommended vaccination with Moderna’s COVID-19 vaccineContinue

Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.
Biotechnology | COVID-19 | FDA | Vaccine

Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.

On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…

Read More Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.Continue

Novavax announced agreement with government of New Zealand for 107 million doses of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax announced agreement with government of New Zealand for 107 million doses of COVID-19 vaccine

On Dec. 16, 2020, Novavax announced an Advance Purchase Agreement with the government of New Zealand for the…

Read More Novavax announced agreement with government of New Zealand for 107 million doses of COVID-19 vaccineContinue

RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics

RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model

On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…

Read More RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical modelContinue

AXIM Biotechnologies completed successful Covid-19 live virus test and filed amended EUA
Biotechnology | COVID-19 | Diagnostics

AXIM Biotechnologies completed successful Covid-19 live virus test and filed amended EUA

On Dec. 15, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…

Read More AXIM Biotechnologies completed successful Covid-19 live virus test and filed amended EUAContinue

INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19

On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…

Read More INOVIO to develop DNA-encoded monoclonal antibody (dMAb) candidates to treat COVID-19Continue

Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing

On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of…

Read More Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testingContinue

CIRM-funded project targeting sickle cell disease received green light for clinical trial
Biotechnology | CRISPR | FDA | Therapeutics

CIRM-funded project targeting sickle cell disease received green light for clinical trial

On Dec.14, 2020, the US Food and Drug Administration (FDA) announced they had granted Investigational New Drug (IND)…

Read More CIRM-funded project targeting sickle cell disease received green light for clinical trialContinue

Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm
Biotechnology | COVID-19 | Therapeutics

Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine storm

On Dec. 14, 2020, Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of…

Read More Incyte announced results of phase 3 study of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 associated cytokine stormContinue

Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19

On Dec. 14, 2020, Moderna confirmed that the Company had concluded an agreement with the Ministry of Health…

Read More Moderna confirmed supply agreement to supply Singapore with mRNA vaccine against COVID-19Continue

CDC’s ACIP issued interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for prevention of COVID-19.
Biotechnology | COVID-19 | Vaccine

CDC’s ACIP issued interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for prevention of COVID-19.

On Dec. 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of…

Read More CDC’s ACIP issued interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged =16 years for prevention of COVID-19.Continue

U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccine

On Dec. 11, 2020, Moderna announced that the U.S. government has exercised its option to purchase an additional…

Read More U.S. Government exercised 1st option for additional 100 million doses of Moderna’s COVID-19 vaccineContinue

Page navigation

Previous PagePrevious 1 … 61 62 63 64 65 … 159 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search